5139-89-9

Usage

Uses

Used in Pharmaceutical Industry:
4-Phenoxybutyryl chloride is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
It is utilized as a building block in the production of pesticides, herbicides, and insecticides, playing a crucial role in enhancing crop protection and agricultural yield.
Used in Perfumery and Flavor Industry:
4-Phenoxybutyryl chloride is employed as a component in the manufacturing of perfumes and flavoring agents, leveraging its aromatic properties to create desirable scents and tastes.
Safety Note:
Due to its corrosive nature, 4-phenoxybutyryl chloride requires careful handling to prevent skin, eye, and respiratory tract irritation upon contact. Proper safety measures should be implemented during its use and storage.

InChI:InChI=1/C10H11ClO2/c11-10(12)7-4-8-13-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2

Upstream product

• 6303-58-8 4-phenyloxybutanoic acid 

Downstream Products

• 101776-83-4 4-phenoxy-butyric acid-(2-dimethylamino-ethyl ester); hydrochloride 
• 500730-12-1 4-phenoxy-butyric acid-(2-nitro-benzylamide) 
• 87841-90-5 5-phenoxypentan-2-one 
• 51992-34-8 4-phenoxybutylnitrile 
• 124901-73-1 4-Phenoxy-N-[6-(4-phenoxy-butyrylamino)-pyridin-2-yl]-butyramide 
• 1448711-03-2 C₂₉H₄₀N₂O₁₃ 
• 1448711-05-4 methyl 5-acetamido-4-phenoxybutyrylamido-3,4,5-trideoxy-D-glycero-α-D-galacto-non-2-ulopyranosidonic acid sodium salt 
• 1224300-67-7 1,1,1,2,2-pentafluoro-6-phenoxyhexan-3-one 
• 6786-30-7 3,4-dihydro-1-benzoxepin-5(2H)-one 

Relevant academic research and scientific papers

Photoinduced, Copper-Catalyzed Decarboxylative C-N Coupling to Generate Protected Amines: An Alternative to the Curtius Rearrangement

The Curtius rearrangement is a classic, powerful method for converting carboxylic acids into protected amines, but its widespread use is impeded by safety issues (the need to handle azides). We have developed an alternative to the Curtius rearrangement that employs a copper catalyst in combination with blue-LED irradiation to achieve the decarboxylative coupling of aliphatic carboxylic acid derivatives (specifically, readily available N-hydroxyphthalimide esters) to afford protected amines under mild conditions. This C-N bond-forming process is compatible with a wide array of functional groups, including an alcohol, aldehyde, epoxide, indole, nitroalkane, and sulfide. Control reactions and mechanistic studies are consistent with the hypothesis that copper species are engaged in both the photochemistry and the key bond-forming step, which occurs through out-of-cage coupling of an alkyl radical.

A simple method for asymmetric trifluoromethylation of N-acyl oxazolidinones via Ru-catalyzed radical addition to zirconium enolates

A Ru-catalyzed direct thermal trifluoromethylation and perfluoroalkylation of N-acyloxazolidinones has been developed. The reaction is experimentally simple and requires inexpensive reagents while providing good yields of products with good levels of stereocontrol. Preliminary studies have shown notable compatibility with functional groups, aromatics, and certain heteroaromatic substituents. The described method provides a useful alternative for the synthesis of fluorinated materials in an experimentally convenient manner.

Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2

Group VIA calcium-independent phospholipase A2 (GVIA iPLA 2) has recently emerged as a novel pharmaceutical target. We have now explored the Structure-activity relationship between fluoroketones and GVIA iPLA2 inhibition. The presence of a naphthyl group proved to be of paramount importance. 1,1,1-Trifluoro-6-(naphthalen-2-yl)hexan-2-one (FKGK18) is the most potent inhibitor of GVIA iPLA2 (XI(50) = 0.0002) ever reported. Being 195 and >455 times more potent for GVIA iPLA 2 than for GIVA cPLA2 and GV sPLA2, respectively, makes it a valuable tool to explore the role of GVIA iPLA 2 in cells and in vivo models. 1,1,1,2,2,3,3-Heptafluoro-8- (naphthalene-2-yl)octan-4-one inhibited GVIA iPLA2 with a X I(50) value of 0.001 while inhibiting the other intracellular GIVA cPLA2 and GV sPLA2 at least 90 times less potently. Hexa- and octafluoro ketones were also found to be potent inhibitors of GVIA iPLA 2; however, they are not selective.

Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: Optimization of in vitro activity

Pyrido pyrimidinones are selective agonists of the human high affinity niacin receptor GPR109A (HM74A). They show no activity on the highly homologous low affinity receptor GPR109B (HM74). Starting from a high throughput screening hit the in vitro activity of the pyrido pyrimidinones was significantly improved providing lead compounds suitable for further optimization.

BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES WITH A CHAIN EXTENSION

The invention relates to substituted cyclohexyl-1,4-diamine derivatives, to a method for their production, to medicaments containing said compounds and to the use of substituted cyclohexyl-1,4-diamine derivatives for producing medicaments.

AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE

The present invention relates to amino alcohol derivatives or phosphonic acid derivatives having excellent immunosuppressive activity, pharmacologically acceptable salts thereof or pharmacologically acceptable esters thereof, and to pharmaceutical compositions comprising said compounds as an active ingredient: [wherein, ???R1 and R2 each represent a hydrogen atom, or a protecting group of the amino group; ???R3 represents a hydrogen atom, or a protecting group of the hydroxyl group; ???R4 represents a lower alkyl group; ???n represents an integer of from 1 to 6; ???X represents an oxygen atom or a nitrogen atom unsubstituted or substituted with a lower alkyl group or the like; ???Y represents an ethylene group; ???Z represents a C1-C10 alkylene group; ???R5 represents an aryl group, or an aryl group substituted with substituents; ???R6 and R7 each represents a hydrogen atom; provided that when R5 represents a hydrogen atom, then Z represents a group other than a single bond or a straight chain C1-C10 alkylene group] .

Polycyclic thiazolidin-2-ylidene amines, process for their preparation, and their use as pharmaceuticals

Polycyclic thiazolidin-2-ylidene amines and their physiologically tolerable salts and physiologically functional derivatives of the formula I in which the radicals have the meanings indicated, and their physiologically tolerable salts and a process for their preparation are described. The compounds are suitable, for example, as anorectics.

Synthesis of 2,6-Diamidopyridine Derivatives and their Functions as Flavin Receptors in Chloroform

It has been found that 2,6-diamidopyridine derivatives act as flavin receptors by a triple hydrogen bond towards a uracil moiety of an isoalloxazine ring in CHCl3.The association constants were determined by 1H NMR (in CDCl3) and fluorescence (in CHCl3) spectroscopies; the largest is ca. 103 mol-1 dm3.The triple hydrogen bond toward C(2)=O, N(3)-H and C(4)=O of the isoalloxazine ring was found to enhance slightly the oxidation activity in CHCl3.

A novel nonpeptide HIV-1 protease inhibitor: Elucidation of the binding mode and its application in the design of related analogs

HIV-1 protease has been identified as a significant target enzyme in AIDS research. While numerous peptide-derived inhibitors have been described, the identification of a nonpeptide inhibitor remains an important goal. Using an HIV-1 protease mass screening technique, 4-hydroxy-3-(3-phenoxypropyl)-2H-1- benzopyran-2-one (1) was identified as a nonpeptide competitive inhibitor of the enzyme. Employing a Monte Carlo-based docking procedure, the coumarin was docked in the active site of the enzyme, revealing a binding mode that was later confirmed by the X-ray crystal analysis. Several analogs were prepared to test the binding interactions and improve the overall binding affinity. The most active compound in the study was 4,7-dihydroxy-3-[4-(2- methoxyphenyl)butyl]-2H-1-benzopyran-2-one (31).